AVR 8.35% $9.99 anteris technologies ltd

Ann: HSV-2 Phase IIa Results Investor Webinar, page-128

  1. 1,142 Posts.
    lightbulb Created with Sketch. 1
    Here's what I am seeing today: speculative buying based on the webinar announcement for a potential pump and dump going into Thursday.

    Only thing that will change the SP med-long term is a collab with $ upfront or milestone payments involved.

    So worst case scenario is that the HSV-2 Vax is a bomb. Right? In that case, we'd - I hope - see AHZ divest itself of the Immunotherapies division immediately making the company CF+ by a large margin in the next 6 months easy.

    If not a bomb then we'd have to see a partnership/collab with the aforementioned up fronts/milestone to justify keep running it.

    So we need decisive action on this now. If a CR is proffered to fund the operational costs of the Vax program I will be very very disappointed.
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
(20min delay)
Last
$9.99
Change
-0.910(8.35%)
Mkt cap ! $211.1M
Open High Low Value Volume
$10.50 $10.79 $9.30 $1.477M 149.3K

Buyers (Bids)

No. Vol. Price($)
1 2000 $9.70
 

Sellers (Offers)

Price($) Vol. No.
$9.99 1999 1
View Market Depth
Last trade - 16.10pm 06/09/2024 (20 minute delay) ?
AVR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.